Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Label-free proteomic profiling of Alzheimer' s disease mice model hippocampus at the age of 8 months

ABSTRACT: Alzheimer’s disease (AD) is the most common form of dementia with high morbidity in the elderly and the hippocampus is one of the key structures severely affected in AD. We performed hippocampal proteomic analysis of 8-month old App-NLF mice model of AD using a liquid-chromatography/mass-spectrometry system to investigate the proteins that are differentially expressed in order to identify changes in the proteins and molecular pathways that might promote the disease.

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Yoshio Goshima

PROVIDER: PXD012541 | JPOST Repository | Wed Feb 05 00:00:00 GMT 2020

REPOSITORIES: jPOST

ACCESS DATA

THIS DATASET HAS BEEN DELETED

Json Xml

Similar Datasets

Phospho-proteomic profiling of Alzheimer' s disease mice model hippocampus at the age of 8 months

Project description:Alzheimer’s disease (AD) is the most common form of dementia with high morbidity in the elderly and the hippocampus is one of the key structures that undergo severe atrophy in AD. We performed hippocampal phospho-proteomic profiling of the App-NLF mice model of AD at the age of 8 months using a liquid-chromatography/mass-spectrometry system to investigate the upregulated and downregulated phosphosites might contribute to the pathogenesis of AD.

2020-01-29 | PXD012543 | JPOST Repository

Expression data from Alzheimer's disease model mouse

2013-04-17 | GSE36981 | GEO

Mouse hippocampus LC/MS with TMT labeling

Project description:Transgenic mouse models have been widely used to investigate the pathology of Alzheimer’s disease (AD). To elucidate underlying mechanisms of AD pathogenesis by amyloid beta (Aβ) and tau, we have generated a novel animal model of AD; ADLP - APT mice (Alzheimer’s Disease-Like Pathology) – carrying mutations of human amyloid precursor protein (APP), human presenilin-1 (PS1) and human tau. We profiled 9,824 proteins in the hippocampus of ADLP model mice using quantitative proteomics. To identify functional signatures in pathology of ADLP - APT mice, in-depth bioinformatics analysis was performed. For a longitudinal change of differentially expressed proteins (DEPs), we identified ADLP - APT mice hippocampal proteome in an age-dependent manner. Network maps of interactome between Aβ and tau in newly generated ADLP - APT mice reveal relationship between accelerated NFT pathology of AD and proteomic changes.

2018-01-25 | PXD006214 | Pride

Patient-based model systems for AD

Project description:The hippocampus is a primary region affected in Alzheimer’s disease (AD). Because AD postmortem brain tissue is not available prior to symptomatic stage, we lack understanding of early cellular pathogenic mechanisms. To address this issue, we examined the cellular origin and progression of AD pathogenesis in patient-based model systems including iPSC-derived brain cells transplanted into the mouse brain hippocampus, as well as human post-mortem hippocampal tissues. Our data showcase patient-based models to study the cellular origin, progression, and prion-like spread of AD pathogenesis.

2023-10-24 | PXD042229 | Pride

Hydroxyurea protects hippocampal neurons against oxidative, metabolic and excitotoxic stress, and improves spatial memory in a mouse model of Alzheimer’s disease (Mouse)

Project description:Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized by accumulation of amyloid β-peptide (Aβ) plaques in the brain and decreased cognitive function leading to dementia. We determined if hydroxyurea (HU), a ribonucleotide reductase inhibitor known to activate adaptive cellular stress responses in fibroblasts, could protect rat hippocampal neurons against oxidative-, excitatory-, mitochondrial-, and Aβ-induced stress and if HU treatment could improve learning and memory in a mouse model of AD (APP/PS1 double mutant transgenic mice). HU treatment attenuated the loss of cell viability induced by treatment of hippocampal neurons with hydrogen peroxide, glutamate, rotenone, and Aβ1-42. HU treatment also attenuated reductions of mitochondrial reserve capacity, maximal respiration, and cellular ATP content induced by hydrogen peroxide treatment. In vivo, treatment of APP/PS1 AD mice with HU (45 mg/kg/day) improved spatial memory performance in the hippocampus-dependent Morris water maze task. In summary, HU provides neuroprotection against toxic insults, improves mitochondrial bioenergetics, and improves spatial memory in a mouse model of AD. HU may offer a new therapeutic approach to delay cognitive decline in AD.

2018-09-10 | GSE111940 | GEO

Hydroxyurea protects hippocampal neurons against oxidative, metabolic and excitotoxic stress, and improves spatial memory in a mouse model of Alzheimer’s disease (Rat)

2018-09-10 | GSE111941 | GEO

Increased glucose uptake in hippocampus as a surrogate biomarker of metabolic reconfiguration of microglia in Alzheimer’s disease

Project description:Microglia is dynamically reprogrammed according to the progression of Alzheimer’s disease (AD). However, clinical translation into biomarker development for functional change in microglia has not been achieved. Here, we find the close association of the metabolic reconfiguration of microglia with increased hippocampal glucose uptake, which can be noninvasively estimated by [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET). We found that increased FDG activity in the hippocampus of an AD mouse model depended on microglial uptake. Single-cell RNA-sequencing of the hippocampus showed the changes of glucose metabolism profiles including glucose transporters, glycolysis and oxidative phosphorylation mainly occurred in microglia. A subset of microglia with high glucose transporters with defective glycolysis and oxidative phosphorylation was increased according to disease progression. Furthermore, we also found a positive association between a soluble TREM2 of cerebrospinal fluid, a marker of microglial activation, and hippocampal FDG uptake as a human study. We identified a reconfiguration of microglial glucose metabolism in the hippocampus of AD and suggested a feasible imaging biomarker based on widely used FDG PET to reflect microglial metabolic profiles.

2021-09-08 | GSE150934 | GEO

Expression data from post mortem Alzheimer's disease brains

2013-04-17 | GSE36980 | GEO

Expression data from post mortem Alzheimer's disease brains

Project description:To identify molecular pathological alterations in AD brains, we performed interspecies comparative microarray analyses using RNAs prepared from postmortem human brain tissues donated for the Hisayama study and hippocampal RNAs from the triple-transgenic mouse model of AD (3xTg-AD) Three-way ANOVA of microarray data from frontal cortex, temporal cortex and hippocampus with presence/absence of AD and vascular dementia, and sex, as factors revealed that the gene expression profile is most significantly altered in the hippocampi of AD brains. Comparative analyses of the brains of AD patients and a mouse model of AD showed that genes involved in non-insulin dependent DM and obesity were significantly altered in both, as were genes related to psychiatric disorders and Alzheimer’s disease. We prepared RNA samples from the gray matter of frontal and temporal cortices and hippocampi derived from 88 postmortem brains, among which 26 cases were pathologically diagnosed as having AD or an AD-like disorder. High-quality RNA (RIN≧6.9) samples were subjected to microarray analysis using the Affymetrix Human Gene 1.0 ST platform, and only those results that passed examinations for quality assurance and quality control of the Human Gene 1.0 ST arrays were retrieved. In total, we obtained gene expression profiles from the following samples: 33 frontal cortex samples, among which 15 were from AD patients; 29 temporal cortex samples, among which 10 were from AD patients; 17 hippocampus samples, among which seven were from AD patients

2013-04-17 | E-GEOD-36980 | biostudies-arrayexpress

Hippocampus Proteomics analysis of 5×FAD::Alb-CreERT2;Ephx2−/− mice and control littermates (5×FAD::Ephx2loxp/loxp); Note: Hepatic Ephx2 deletion in 5×FAD::Alb-CreERT2;Ephx2−/− mice

Project description:Alzheimer’s disease (AD) is the leading cause of late onset dementia. However, to date, no efficient therapy for AD is available. Here, we identified a neuroprotective role of the liver contributing to brain amyloid-β (Aβ) homeostasis. The hippocampus is a crucial region for learning and memory and is one of the brain areas most affected by AD. To investigate brain mechanisms underlying the neuroprotective role of the liver in AD pathology, we performed proteomics analysis of hippocampus extracted from 5×FAD::Alb-CreERT2;Ephx2−/− mice and control littermates. After quality control, we identified 67 protein expressions that were differently regulated between the two genotypes, including nine proteins in the Kyoto Encyclopedia of Genes and Genomes pathway of AD

2023-06-22 | PXD037361 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data